Hidradenitis Suppurativa Market Report 2026

The hidradenitis suppurativa market size has grown strongly in recent years. It will grow from $1.24 billion in 2025 to $1.33 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing prevalence of chronic inflammatory skin disorders, improved dermatology diagnostic capabilities, rising awareness of hs symptoms, expansion of dermatology clinics, availability of antibiotic treatment options.

The hidradenitis suppurativa market size is expected to see strong growth in the next few years. It will grow to $1.75 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to growing demand for targeted biologic drugs, increasing focus on long-term disease management, expansion of personalized dermatology care, rising adoption of advanced laser therapies, increasing investment in chronic skin disease research. Major trends in the forecast period include increasing adoption of biologic therapies for hs, rising use of minimally invasive surgical treatments, growing focus on early disease diagnosis, expansion of combination treatment approaches, enhanced patient-centric care models.

The increasing prevalence of skin diseases is expected to drive the growth of the hidradenitis suppurativa market in the coming years. Skin diseases encompass a wide range of conditions, including those caused by bacterial, viral, or fungal infections, allergies, skin cancers, and parasitic infestations. Hidradenitis suppurativa (HS), a chronic and severe skin disorder, is fueling the development of new treatments and services due to greater awareness, improved diagnostic accuracy, an expanding patient population, and ongoing research advances. For example, in January 2024, according to the American Cancer Society, a US-based non-profit organization focused on cancer elimination, there were 108,270 reported cases of skin cancer, marking a 3.2% increase from the 104,930 cases reported in 2023. This rise in skin disease prevalence is driving the expansion of the hidradenitis suppurativa market.

Leading companies in the hidradenitis suppurativa market are prioritizing the development of advanced biologic therapies to enhance treatment outcomes and address unmet medical needs. Biologics are medications derived from living organisms that specifically target components of the immune system involved in disease progression. For instance, in June 2023, Novartis AG, a Switzerland-based pharmaceutical company, received European regulatory approval for Cosentyx for the treatment of hidradenitis suppurativa. Cosentyx is the first fully human biologic that selectively inhibits interleukin-17A, a cytokine central to HS pathophysiology. With over 14 years of clinical research, Cosentyx provides a well-established, targeted therapeutic option, strengthening Novartis’s position in the hidradenitis suppurativa market.

In July 2025, Novartis AG reached an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) to enhance access to Cosentyx® for patients with hidradenitis suppurativa in Canada. The collaboration aims to improve patient access to innovative biologic therapy, optimize treatment outcomes, and support the broader adoption of effective HS management nationwide. The pan-Canadian Pharmaceutical Alliance is a Canada-based non-profit organization that negotiates drug pricing on behalf of Canadian public drug plans.

Major companies operating in the hidradenitis suppurativa market are AbbVie Inc., Pfizer Inc., Johnson & Johnson, Novartis AG, Eli Lilly and Company, UCB S.A., LEO Pharma A/S, Almirall S.A., AstraZeneca plc, Bayer AG, Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Taro Pharmaceutical Industries Ltd., AnaptysBio Inc., Acelyrin Inc., Arcutis Biotherapeutics Inc., Priovant Therapeutics, Aristea Therapeutics, Union Therapeutics, Revance Therapeutics.

North America was the largest region in the hidradenitis suppurativa market in 2025. The regions covered in the hidradenitis suppurativa market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hidradenitis suppurativa market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hidradenitis suppurativa market by increasing costs of imported biologic drugs, injectable delivery systems, surgical instruments, and dermatology medical devices. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported advanced therapies, while developing regions experience higher treatment costs. These tariffs are contributing to pricing pressure and slower adoption of novel treatments. However, they are also encouraging local pharmaceutical manufacturing, regional clinical trial activity, and domestic production of dermatology treatment solutions.

The hidradenitis suppurativa market research report is one of a series of new reports that provides hidradenitis suppurativa market statistics, including hidradenitis suppurativa industry global market size, regional shares, competitors with a hidradenitis suppurativa market share, detailed hidradenitis suppurativa market segments, market trends and opportunities, and any further data you may need to thrive in the hidradenitis suppurativa industry. This hidradenitis suppurativa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hidradenitis suppurativa (HS) is a chronic skin disorder characterized by painful lumps that develop deep within the skin, typically in areas where skin rubs against skin, such as the armpits, inner thighs, and groin.

The main types of skin conditions associated with hidradenitis suppurativa include folliculitis, pimples, boils, and deep acne. Folliculitis is a common condition in which hair follicles become inflamed or infected, and it can be treated using creams, oral medications, or laser hair removal therapies. Treatments for HS include tablets and intravenous (IV) injections, administered through oral and parenteral routes, as well as interventions such as medications, surgery, photodynamic therapy (PDT), laser therapy, and others. These treatments are provided to end users including hospitals, specialty clinics, homecare services, and other healthcare settings.

The hidradenitis suppurativa (HS) market consists of revenues earned by entities providing treatment to axillary-mammary-inguinal hidradenitis suppurativa, follicular hidradenitis suppurativa, gluteal hidradenitis suppurativa, and syndromic hidradenitis suppurativa. The market value includes the value of related goods sold by the service provider or included within the service offering. The hidradenitis suppurativa (HS) market also includes sales of surgery biologics, antibiotics, immunosuppressive drugs, zinc supplements, and retinoids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.